更新于：2024-11-21

Propiolactone

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

小分子化药

别名

Betaprone

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Forest Laboratories, Inc.

在研机构-

非在研机构

Forest Laboratories, Inc.

最高研发阶段撤市

首次获批日期

美国 (1959-06-12)

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C3H4O2

InChIKeyVEZXCJBBBCKRPI-UHFFFAOYSA-N

CAS号57-57-8

关联

100 项与 Propiolactone 相关的临床结果

登录后查看更多信息

100 项与 Propiolactone 相关的转化医学

登录后查看更多信息

100 项与 Propiolactone 相关的专利（医药）

登录后查看更多信息

321

项与 Propiolactone 相关的文献（医药）

2023-06-30·Viruses

Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials.

Article

作者: Carvalho, Milena Mouta Verdan França ; Neves, Patrícia Cristina da Costa ; Esteves, Gabriela Santos ; Gomes, Mariana Pierre de Barros ; Mendes, Ygara da Silva ; Linhares, José Henrique Rezende ; da Silva, Juliana Fernandes Amorim ; Schwarcz, Waleska Dias ; Barreto-Vieira, Débora Ferreira ; Gomes, Viviane Silva ; Ano Bom, Ana Paula Dinis ; Müller, Rodrigo ; Souza, Marta Cristina de Oliveira ; Santos, Renata Tourinho ; Missailidis, Sotiris ; da Silva, Stephanie Almeida ; Trindade, Gisela Freitas ; Dos Santos, Tiago Pereira ; de Lima, Sheila Maria Barbosa ; Pereira, Renata Carvalho ; Gardinali, Noemi Rovaris ; Moura, Luma da Cruz ; Alves, Nathalia Dos Santos

Successful SARS-CoV-2 inactivation allows its safe use in Biosafety Level 2 facilities, and the use of the whole viral particle helps in the development of analytical methods and a more reliable immune response, contributing to the development and improvement of in vitro and in vivo assays. In order to obtain a functional product, we evaluated several inactivation protocols and observed that 0.03% beta-propiolactone for 24 h was the best condition tested, as it promoted SARS-CoV-2 inactivation above 99.99% and no cytopathic effect was visualized after five serial passages. Moreover, RT-qPCR and transmission electron microscopy revealed that RNA quantification and viral structure integrity were preserved. The antigenicity of inactivated SARS-CoV-2 was confirmed by ELISA using different Spike-neutralizing monoclonal antibodies. K18-hACE2 mice immunized with inactivated SARS-CoV-2, formulated in AddaS0₃^TM, presented high neutralizing antibody titers, no significant weight loss, and longer survival than controls from a lethal challenge, despite RNA detection in the oropharyngeal swab, lung, and brain. This work emphasizes the importance of using different techniques to confirm viral inactivation and avoid potentially disastrous contamination. We believe that an efficiently inactivated product can be used in several applications, including the development and improvement of molecular diagnostic kits, as an antigen for antibody production as well as a control for non-clinical trials.

2023-02-01·iScience

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals

Article

作者: Zhou, Yuyong ; Offersgaard, Anna ; Fernandez-Antunez, Carlota ; Gammeltoft, Karen Anbro ; Fahnøe, Ulrik ; Pham, Long V ; Gottwein, Judith Margarete ; Alzua, Garazi Peña ; Ramirez, Santseharay ; Jensen, Henrik Elvang ; Feng, Shan ; Pedersen, Gabriel Kristian ; Holmbeck, Kenn ; Schneider, Uffe Vest ; Pihl, Anne Finne ; Marichal-Gallardo, Pavel ; Bukh, Jens ; Hartmann, Katrine Top ; Christensen, Jan Pravsgaard ; Duarte Hernandez, Carlos Rene

Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralizing antibodies in mice; moreover, lyophilized antigen was immunogenic. Following homologous challenge, I-SARS-CoV-2 immunized hamsters were protected against disease and lung pathology. In contrast with reports for widely used vaccines, hamster plasma similarly neutralized the homologous and the Delta (B.1.617.2) variant viruses, whereas the Omicron (B.1.1.529) variant was neutralized less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage.

2022-08-01·Vaccine

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus

Article

作者: Excler, Jean-Louis ; Sumathy, K ; Sahastrabuddhe, Sushant ; Smith, Emily R ; Chen, Robert T ; Gurwith, Marc ; Hernandez, Libia Milena ; Kochhar, Sonali

Inactivated viral vaccines have long been used in humans for diseases of global health threat (e.g., poliomyelitis and pandemic and seasonal influenza) and the technology of inactivation has more recently been used for emerging diseases such as West Nile, Chikungunya, Ross River, SARS and especially for COVID-19. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has prepared standardized templates to describe the key considerations for the benefit and risk of several vaccine platform technologies, including inactivated viral vaccines. This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical studies and clinical trials. The inactivated whole CHIKV vaccine was cultured on Vero cells and inactivated by ß-propiolactone. This provides an effective, flexible system for high-yield manufacturing. The inactivated whole CHIKV vaccine has favorable thermostability profiles, compatible with vaccine supply chains. Safety data are compiled in the current inactivated whole CHIKV vaccine safety database with unblinded data from the ongoing studies: 850 participants from phase II study (parts A and B) outside of India, and 600 participants from ongoing phase II study in India, and completed phase I clinical studies for 60 subjects. Overall, the inactivated whole CHIKV vaccine has been well tolerated, with no significant safety issues identified. Evaluation of the inactivated whole CHIKV vaccine is continuing, with 1410 participants vaccinated as of 20 April 2022. Extensive evaluation of immunogenicity in humans shows strong, durable humoral immune responses.

100 项与 Propiolactone 相关的药物交易

登录后查看更多信息